… lung cancer samples from US patients who responded to gefitinib therapy and in a lung …
hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell …

… helped to define the characteristics of patients most likely to respond to gefitinib therapy. …
has helped to define the characteristics of patients most likely to respond to gefitinib therapy. …

… All published trials and abstracts citing gefitinib were … Gefitinib, with a unique mechanism
of action and favorable toxicity … Further research is required to evaluate the use of gefitinib in …

… However, unlike NSCLC patients who receive gefitinib first-line, outcome from gefitinib
therapy in patients who had previously received chemotherapy appears to be consistent across …

… Sixteen patients were enrolled and treated with gefitinib. Twelve … gefitinib is very active and
well tolerated as first-line therapy … In conclusion, gefitinib treatment as first-line therapy for …

… In the ONCOBELL cohort, no patient had gene amplification and MET gene copy number
was not associated with outcome to gefitinib therapy. Among the surgically resected patients, …

… with NSCLC after failure of first-line gefitinib, we carried out a … -line antitumor treatment after
gefitinib therapy. Clinical data … first-line gefitinib and at least 1 subsequent line therapy were …

… Areas covered: All published data on gefitinib in lung cancer were analyzed using PubMed.
… of gefitinib in patients with advanced NSCLC. Expert opinion: EGFR-TKIs including gefitinib …

… , this patient obtained SD with an initial gefitinib therapy of 4.3 months, and therefore we
considered this patient to have benefited from the gefitinib treatment. Further clinical trials are …

… The INTEREST (IRESSA NSCLC trial evaluating response and survival against taxotere)
trial reported survival following gefitinib therapy was not inferior to docetaxel chemotherapy in …